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SUPPLEMENTARY APPENDIX

Supplementary Design and Methods
Culture conditions and reagents
The complete culture medium used for the mixed lymphocyte culture (MLR) was X-Vivo 15 medium (BioWhittaker, Verviers, Belgium) supplemented with 5% pooled AB human serum (Biowhittaker) and 100 U/mL penicillin/streptomycin (Bristol-Myers Squibb, Sermoneta, Italy). The culture medium for analysis of cytotoxic T lymphocyte precursors (CTLp) was Iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum (Biowhittaker), 100 U/mL penicillin/streptomycin (Bristol-Myers Squibb), and 2 mM L-glutamine (GIBCO BRL, Gaithersburg, MD, USA). All cultures were incubated at 37°C in a humidified air incubator with 5% CO2. Human recombinant transforming growth factor-β (TGF-β) was purchased from R&D Systems (Minneapolis, MN, USA). CD3-coupled magnetic beads were purchased from Dynal (Oxoid, Milan, Italy). Neutralizing anti-interleukin-10 receptor (clone 3F9) was obtained from BD PharMingen (San Diego, CA, USA) and anti-TGF−β1,2,3 (clone 1D11) from R&D systems. 
Antigen-specific responses
Cytotoxic T lymphocyte precursor frequency assay
MLR cells cultured in the presence of interleukin-10 (IL-10) (MLR/10) were tested for the frequency of CTLp for the original allogeneic stimulator cells. Results were compared to those obtained from a primary MLR in the absence of IL-10. The CTLp frequency assay was performed as previously described. 2 Briefly, MLR and MLR/10 responder cells were plated in 2-or 3-fold limiting dilution (starting concentration of 5¥10 4 for haploidentical pairs and 5¥10 3 for mismatched pairs) in 20 replicates for each dilution, in the presence of 5¥10 4 irradiated (6000 rad) CD3-depleted or total peripheral blood mononuclear cells (PBMC) of the original stimulator. Cultures were performed in the presence of 90 IU/mL recombinant human interleukin-2 (hIL-2; Chiron Italia, Milan, Italy). In parallel, a T-cell line of the stimulator was established by plating 2¥10 6 /mL PBMC with 1 mg/mL phytohemagglutinin (PHA) (Sigma) in the presence of rhIL-2 (600 IU/mL). On day 10, individual wells were tested for cytotoxic activity against the Cr-release assay, effector and target cells were incubated for 4 h at 37°C; subsequently the supernatants were removed and counted in a γ-counter. The percentage of specific release was calculated using the following formula: 100*(51Cr-release in the supernatantspontaneous release)/(total release into detergent-spontaneous release). For calculation of CTLp frequencies, the fraction of negative wells was plotted for each dilution on a semi-logarithmic scale and the dilution in which 37% of wells were negative corresponded to the calculated frequency. 3 A positive and a negative control were included in the CTLp assay of each donor pair. The positive control was the cytotoxic activity of an unrelated responder against the specific stimulator cells used in the MLR, whereas the negative control was the autologous cytotoxic activity. The mean of lytic activity [cpm + 3SD] of the 20 autologous control wells was used as the cut-off value for evaluation of positive wells. Epstein-Barr virus (EBV)-specific CTLp frequencies were analyzed and calculated as described above for alloantigen-specific CTLp, but autologous to the responder EBV-LCL (previously established incubating PBMC with B95.8 viral supernatant) were used as stimulators for the 10-day in vitro culture period (3¥10 4 irradiated by 10000 Rad) as well as readout targets for the cytotoxic assay.
For in vitro induction of effector cells specific for the immunodominant influenza protein-derived peptide MP.58-66, CD8-enriched T cells from HLA-A*0201 + healthy donors were obtained from PBMC depleted of CD19 + and CD4 + cells by immunomagnetic beads. Mixed-lymphocytepeptide stimulations were performed as follows: 2¥10 6 /well T cells were seeded in 24-well plates with 10 mg/mL MP.58-66 peptide, in the presence or absence of IL-10 (10 ng/mL). On day 2, IL-2 (10 IU/mL) was added. Responder CD8 + T cells were stimulated weekly as described with autologous irradiated monocytes (CD3 -CD19 -PBMC) previously pulsed with the MP.58-66 peptide. The responder populations were analyzed after the second stimulation for lytic activity and interferon-γ release against MP.58-66 pulsed and unpulsed T2 cells. MP.58-66-specific CD8 + T cells in culture can be traced by Vβ17 expression, the dominant Vβ chain used by MP.58-66-specific T cells 4 or by A2/MP.58-66 tetramers.
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Flow cytometric analysis
Anti-CD4, -CD8, CD14, -CD25, -CD28, HLA-DR, -CD14, -CD1a, and -CD83 monoclonal antibodies, directly coupled to fluoroscein isothiocyanate or phycoerythrin, were purchased from BD Bioscience. Cells were incubated with the indicated monoclonal antibodies for 20 min at 4°C in phosphate-buffered saline 2% fetal calf serum, washed twice and analyzed using a FACScan flow cytometer (BD Biosciences), and data were analyzed with CellQuest software (BD Biosciences).
RNA sampling and SuperAmplification
Total PBMC were activated with allogeneic monocytes in the absence (MLR) or in the presence of IL-10 (MLR/10) or with allogeneic DC-10 (MLR/DC-10) or mature dendritic cells (MLR/mDC). After 10 days, cells were collected and lysed using SuperAmp™ lysis buffer (Miltenyi Biotec GmbH, Germany) following the manufacturer's instructions and stored at -80°C. DNA microarray analysis of gene expression was performed at Miltenyi Biotec's Genomics Service facility (Bergisch Gladbach, Germany), using Agilent technology (Agilent Technologies, Inc.). SuperAmplification was performed according to the manufacturer's instructions. Briefly, cell samples were collected in 6.4 mL lysis buffer (including detergent, tRNA and protease), the mRNA extracted using magnetic beads and transcribed into cDNA using tagged random and oligo(dT) primer. First strand cDNA was 5' tagged using terminal deoxynucleotidyl transferase (Fermentas). Tagged cDNA was globally amplified (Expand Long Template PCR System DNA Pol Mix, Roche) using primer complementary to the tag sequence. Amplified cDNA were quantified using an ND-1000 spectrophotometer (NanoDrop Technologies, Inc). The integrity of the cDNA was checked via the Agilent 2100 Bioanalyzer platform (Agilent Technologies, Inc.).
Hybridization of Agilent whole human genome oligo microarrays
Two hundred and fifty nanograms of the purified polymerase chain reaction product (NucleoSpin ® Extract II Kit, Macherey & Nagel) were labeled with Cy3-dCTP (GE Healthcare) in a Klenow Fragment reaction. Finally, 1.25 mg Cy3-labeled and purified (CyScribe GFX Purification Kit, GE Healthcare) cDNA in hybridization buffer were hybridized overnight (17 h, 65°C) to 4x44K Agilent Whole Human Genome Oligo Microarrays using Agilent's recommended hybridization chamber and oven. Following hybridization, the microarrays were washed once with Agilent gene expression wash buffer 1 for 1 min at room temperature followed by a second wash with preheated (37°C) Agilent gene expression wash buffer 2 containing 0.005% N-lauroylsarcosine for 1 min. The last washing step was performed with acetonitrile for 30 sec.
Scanning and data analysis
Fluorescence signals of the hybridized Agilent microarrays were detected using Agilent's microarray scanner system (Agilent Technologies). The Agilent feature extraction software (FES, v.9.5.1.1.) was used to read out and process the microarray image files. For determination of differential gene expression FES-derived output data files were further analyzed using the Rosetta Resolver gene expression data analysis system (v.7.1.0.0. Rosetta Inpharmatics LLC). Ratios were computed for each sample/control pair and transformed to a log2 scale. Additionally, P values indicating the reliability of an observed difference between a sample and its corresponding control were calculated for each gene applying the universal error model implemented in the Rosetta Resolver software. 6 Only expression values with P values less than 0.01 were considered statistically significant. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus 7 and are accessible through GEO Series accession number GSE17493 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17493).
Genes which were at least 1.7-fold up-or down-regulated in at least two of the three biological replicates (and the same trend of expression in the third replicate) of both the comparisons "MLR/10 versus MLR" and "MLR/DC-10 versus MLR/mDC" were selected and analyzed for a statistically significant enrichment of biological pathway annotation terms. Term enrichment relative to the expected background distribution was scored using Fisher's exact test. Annotations were derived from publicly available and literature-derived data sources, e.g. Gene Ontology (GO, www.geneontology.org), signaling pathway membership, sequence motifs, chromosomal proximity, literature keywords, and cellspecific marker genes. 
